Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID‐19) and the rationale for their utilization: A review
Richard Giovane, Shadi Rezai, Ellen Cleland, Cassandra E. Henderson
Abstract
SARS-CoV-2 has caused a pandemic which is putting strain on the health-care system and global economy. There is much pressure to develop both preventative and curative therapies for SARS-CoV-2 as there is no evidence to support therapies to improve outcomes in patients with SARS-CoV-2. Medications that inhibit certain steps of virus life cycle that are currently used to treat other illnesses such as Malaria, Ebola, HIV and Hepatitis C are being studied for use against SARS-CoV-2. To date, data is limited for medications that facilitate clinical improvement of COVID-19 infections.
Topics & Concepts
MedicinePandemicIntensive care medicineCoronavirus disease 2019 (COVID-19)CoronavirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DiseaseModalitiesMalariaEbola virus2019-20 coronavirus outbreakVirologyImmunologyOutbreakInfectious disease (medical specialty)Internal medicineSociologySocial scienceCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19